Primed for take-off

Philippe Leboulch ()
Additional contact information
Philippe Leboulch: Philippe Leboulch is at the Institute of Emerging Diseases and Innovative Therapies, CEA, INSERM, University of Paris 11, 92265 Fontenay-aux-Roses, France. He is also at the Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

Nature, 2013, vol. 500, issue 7462, 280-282

Abstract: Gene therapy is finally getting a bumper crop of data that show clinical efficacy after fine-tuning of key parameters that control safety and potency. Supporting evidence comes from treatment of two life-threatening human diseases.

Date: 2013
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/500280a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:500:y:2013:i:7462:d:10.1038_500280a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/500280a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().